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Alternative Medicine in the
Elderly: Use and Abuse
The use of alternative medical practices
and herbal supplements grows each
year. Many seniors welcome these
adjunct treatments into their lifestyles.
Our authors examine the pros and
cons of some of the more common sup-
plements and herbs.
Piero Antuono, M.D., is a Professor of Neurology and
Pharmacology at the Medical College of Wisconsin in
Milwaukee. He is the director of the Dementia
Research Center and the Medical Board of the
Southeastern Wisconsin Chapter of the Alzheimer's
Association. He is also Vice-Chairman of the Study
Group on Dementia of the World Federation of
Neurology and researches identifying early life risk fac-
tors and the functional MRI patterns in aging and
Alzheimer's Disease.
Jan Beyer, BSN, RN is Patient Services Manager in the
Department of Neurology at the Medical College of
Wisconsin. She coordinates services for Dementia
Research Center, including the Memory Disorders
Clinic, and co-facilitates an Alzheimer's Disease
Support Group for caregivers.
Jennifer Jones, M.S. is a Senior Research Technologist
in the Medical College of Wisconsin Department of
Neurology. She oversees the Wisconsin Alzheimer's
Disease Brain Tissue Bank and coordinates research
projects on Alzheimer's Disease, mild cognitive impair-
ment, functional MRI, and MR spectroscopy.
By Piero Antuono, Jennifer Jones,
and Jan Beyer
omplementary or alternative medicine
(CAM) is defined as "a broad domain
of healing resources that encompasses
all health systems, modalities, prac-
tices, and their accompanying theories
and beliefs, other than those intrinsic to the politi-
cally dominant health system of a particular society
or culture in a given historical period."1 In the
United States, it has become an increasingly popu-
lar mode of therapy, with approximately one-third
of all Americans visiting an alternative healthcare
practitioner. The number of these visits, estimated
to be four million, is more numerous than conven-
tional visits to traditional physicians. Costs for
these services have been estimated at more than
$13 billion, most of it not reimbursed by healthcare
providers.2 What is considered to be CAM in the
Western World is classified as traditional medicine
in other parts of the world.3 In fact, up to eighty
percent of the world's health care is considered
alternative medicine in the West.
CAM has gradually expanded in some Western
countries, such as Germany and Australia, where
up to seventy percent of all health care interven-
tions involve CAM.4 As a result, consumers, as well
as health care professionals, are showing a growing
interest in CAM. Approximately fifty percent of
United States physicians have used CAM practices
and perceive these modalities as having some effi-
cacy.' In Europe, acupuncture is widely used in
pain clinics, and herbal products are among the
most frequently prescribed medications. Almost a
third of specialty residencies for physicians in the
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United States offer some courses in CAM, and thir-
ty-two medical schools offer courses in CAM.6
The National Library of Medicine biographic
database has recently started to collect scientific
documentation on CAM. At the rate of twelve per-
cent per year, the number of these citations is
steadily increasing and is almost double the growth
of traditional medical literature topics from the
National Institutes of Health. The Institutes has
established an Office of Alternative Medicine to
promote studies in this area. Despite more than
600 worldwide journals that report CAM research,
the overall quality of this research is regarded as
poor, with little understanding of the mechanism of
action of several of these interventions.
Despite possible risks, however, the potential
benefits of some CAM practices is significant, such
as access to low-cost pharmacological intervention
or the use of treatments that may not rely on drugs,
such as acupuncture or manipulation. Scientific
studies are currently underway to study the effect
of vitamins and nutritional supplements in diseases
such as Alzheimer's disease, benign prostatic hyper-
trophy, and heart disease; thus far, results are
promising. As the body of scientifically valid
knowledge on CAM broadens, these alternative
modes of treatment will likely become integrated
with traditional medicine. For instance, there is evi-
dence that acupuncture,7 vitamin supplements,
herbal products,' diet, 9 and medication' may have
a therapeutic benefit for arthritis sufferers.
In 1990, more than eighty percent of CAM con-
sumers also used conventional medicine interven-
tions." Most people who use alternative medicine
intervention do so, not because they refuse tradi-
tional medicine, but rather as an additional inter-
vention. 2 Herbs are generally sold and recom-
mended by the public. These consumers rely on
anecdotal evidence rather than scientific proof.
Frequently the lay public believes "natural"
equates with "safe," which means there are no side
effects and no drug interactions. This concept is
obviously erroneous. Most nutritional products
can be just as dangerous as prescription drugs and
possibly more dangerous, as there is not much
known about their mode of action. The traditional
healthcare professional has a pivotal role in coun-
seling the consumer about valid CAM practices to
be used in conjunction with traditional medicine.
CAM users include patients of all ages and cultur-
al backgrounds. With the growing number of
healthy elderly, CAM is used increasingly as an
intervention to maintain "healthy aging." At times,
the high cost of traditional pharmaceuticals results
in the elderly being more receptive to the lure of
CAM practices.
At the present time, approximately fifty percent
of patients use CAM. The market for natural prod-
ucts is projected to be $6.5 billion in the year 2001,
a growth of one hundred percent since 1994.
Unlike prescription and over-the-counter medica-
tions which have been deemed safe and effective by
the FDA, herbal products are labeled as "dietary
supplements" according to the Dietary Supplement
and Health Education Act of 1994. As dietary sup-
plements these compounds can make "structure
and function claims" but cannot make any health
or therapeutic claims. 3 These products may include
accompanying literature if "a balanced view" is
presented, but a statement about safety cannot be
made without FDA evaluation. Therefore, a dis-
claimer stating that these compounds have not
been evaluated by the FDA is required. The label
must state that the product is not intended to diag-
nose, treat, cure, or prevent a disease, but rather is
a dietary supplement intended solely for nutrition-
al support. The manufacturing of herbal products
is an unregulated process. Most preparations are
not standardized. Variable manufacturing meth-
ods, herbal concentrations, and additives can deter-
mine the herbal product's purity, the rate at which
it is absorbed in the body, the maximum possible
effect, and the dose needed to reach this effect.
Most of the research and professional literature
on these compounds comes from Europe and Asia.
In Germany, a special commission (Commission E)
was set up in 1978 to review and approve herbal
treatments; recommendations are based on safety,
historical data, and efficacy studies. There are sev-
eral herbal drugs that are potentially dangerous.
For instance, efedra (Ma Haung) contains
ephedrine and is frequently used in combination
with caffeine, which can have a strong stimulatory
effect on the heart. Efedra caused several deaths in
the United States before the FDA intervened and
withdrew its use. Another, pennyroyal is used to
induce abortion or delay menses, but it is toxic to
the liver and the central nervous system. Comfrey,
used topically on wounds, and internally for gastric
ulcers, contains hepatotoxic pyrrizolidine alka-
loids. Another questionable product is 5-HTP
(hydroxytryptophan) used for depression, weight
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loss, and insomnia; it may cause gastric distress and
possible heart valve problems.
Vascular Disease
Gingko biloba is one herbal product that has fre-
quently been discussed in the literature, specifically
for conditions affecting the elderly. This herb, an
extract from a leaf of the gingko tree, is one of the
most widely prescribed drugs in Europe. It is pri-
marily used to treat decreased peripheral vascular
circulation, dementia, and impotence based on vas-
cular disease. It is also widely used as an antioxi-
dant, antiallergy medication, and anticlotting
agent. However, it is not an innocuous drug since it
may interfere with other drugs that affect clotting,
such as Coumadin and Heparin. Individuals using
aspirin and ibuprofen should also use it with cau-
tion. Gingko may reduce blood pressure and there-
fore should not be used with nutritionals, that have
a similar effect, such as St. John's Wort (SJW).
Many double-blind studies on gingko, most
reported in the German literature, have been car-
ried out. A meta-analysis of forty studies found
gingko to be useful in improving symptoms such as
difficulty in concentration, memory, confusion,
dizziness, headaches, and depression. 4 Nine dou-
ble-blind randomized clinical trials with gingko for
intermittent claudication demonstrated that it
could increase pain-free walking by seventy-five to
one hundred ten percent. Gingko was shown to be
helpful for claudication in a study in which patients
were evaluated on a treadmill. After twenty-four
weeks of treatment, the treated group could walk
twice as fast as the placebo group. A small study of
gingko in Alzheimer's disease and multi-infarct
dementia in 216 patients demonstrated a signifi-
cant positive response in twenty-eight percent of
patients taking gingko versus ten percent of place-
bo patients.ls A more recent study reported in
JAMA of 309 patients with many types of demen-
tia demonstrated a positive response for one year."
The study was, however, fraught with a high
dropout rate, and only a moderate response on
memory and activities of daily-living scales, which
was approximately half of what conventional
memory drugs, such as donepezil and rivastigmine,
demonstrated. Gingko has been tested in
Alzheimer's disease in Europe with overall mixed
results. Two large United States-based multicenter,
placebo-controlled studies are underway and
results should be available in several years.
Gingko has also shown efficacy in treating sex-
ual dysfunction in patients receiving antidepres-
sants. In one study, eighty-four percent of subjects
reported positive effects related to libido, erection,
orgasm, and resolution. 7
Vitamin E, also known as Tocopherol, has been
used for angina, arteriosclerosis, high cholesterol,
dementia, and Alzheimer's disease. Vitamin E is an
antioxidant and thus inhibits platelet aggregation,
which can prolong bleeding. Recently, it has been
shown that vitamin E may limit the amounts of
LDL cholesterol and therefore reduce the risk of
heart disease. All of these findings are not com-
pletely substantiated, and currently vitamin E is
used as a preventative agent rather than a thera-
peutic one. It is known that Tocopherol, a form of
vitamin E, is easily absorbed by the body. Another
form, Tocopheryl acetate is more difficult to absorb
and has a longer shelf life. Therefore, smaller doses
of Tocopheryl acetate may be indicated due to its
longer mode of action. Furthermore, the D form of
vitamin E is thought to be more effective than the
"D,L" form, which is a synthetic form of vitamin
E. Vitamin E has been tested in Alzheimer's disease
in the United States. It appeared to be as effective
as the prescription drug, Selegiline, in postponing
time of admission to a nursing home, time of death,
and significant loss of activities of daily living.
Vitamin E is generally well tolerated but can pro-
long bleeding time. It is currently being tested with
the prescription drug, Donepezil, in a multicenter
trial for the prevention of Alzheimer's disease.
The root of ginseng has long been used in Asia
for the treatment of memory loss associated with
aging, as well as to fight infection and to increase
mental alertness. Most of these claims remain
unsubstantiated, and, in fact, studies have shown
no difference from placebos. The most commonly
recognized effect of ginseng is a caffeine-like
response, which may explain its common side
effects of insomnia and agitation. Because of these
effects, it should be avoided in people with high
blood pressure.
Chronic venous insufficiency, a common ail-
ment in the elderly, has been studied with horse
chestnut seed extract (HCSE). The active ingredient
of HCSE is escin, an anti-inflammatory drug that
inhibits protolytic enzymes thus promoting colla-
gen and elastin formation. Of thirteen studies
reported in the German literature, eight of which
were placebo controlled, and five of which were an
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active comparator, involving a total of 1083
patients, HCSE was found superior to placebo in
eliminating signs of venous insufficiency."8
Commission E recommended that HCSE "repre-
sents a treatment option worth considering." In a
second study comparing HCSE and compression
stockings in 240 patients, HCSE was as effective as
compression stockings and five times more effec-
tive than placebo.' 9
Arthritis
Glucosamine and chondroitin are components of
the cartilage matrix and stimulate cartilage forma-
tion. Their main indication is degenerative joint
disease. When chondroitin was compared to
diclofenac, a potent anti-inflammatory drug,
diclofenac worked faster but chondroitin worked
better and lasted longer after cessation of treat-
ment.2" When glucosamine was compared to
ibuprofen, in a double-blind study with forty
patients, the effect of glucosamine was better than
ibuprofen at eight weeks of treatment, with less
than half of the side effects of ibuprofen. In a
three-year study of osteoarthritis of the knee in 212
patients, glucosamine improved x-ray findings at
one and three years, and increased joint space from
baseline.
Prostatic Disease
Urinary frequency in aging men is a common com-
plaint often related to prostatic hypertrophy. Saw
palmetto (serenoa repens), a plant native to the
southeastern United States, has antiandrogenic,
antiestrogenic, and anti-inflammatory properties. It
.can decrease prostate size, help urinary symptoms
within one month, and has no effect on PSA levels.
A three-month open label trial using saw palmetto
150 mg twice daily in 505 patients demonstrated
significant responses on urodynamic measures of
mean flow, residual volume, and prostatic volume.
A double-blind placebo-controlled study in 110
patients with the same dose demonstrated signifi-
cant reduction in nocturia, dysuria flow rate, and
post-void residual.' A comparative study between
160 mg twice daily of saw palmetto and 5 mg of
finasteride in 1098 men with moderate benign pro-
static hypertrophy (BPH) demonstrated that saw
palmetto and finasteride were clinically equivalent
in the treatment of men with 'mild to moderate
symptoms of BPH. There were no significant dif-
ferences in adverse events.23 Two meta-analyses of
eighteen trials (2139 patients) using saw palmetto
and twenty-five trials (6840 patients) using alpha-1
blockers demonstrated that both compounds were
equally effective in reducing symptoms of prostatic
hypertrophy when compared to the placebo-treat-
ed patients. Dropouts and adverse events were
fewer in the saw palmetto group.24
Depression
St. John's Wort (SJW) is among the most common-
ly used aids for depression, a frequent condition in
the elderly. Its active ingredient, hypericin, appears
to inhibit monoamine oxidase and prevent sero-
tonin uptake mechanisms targeted by conventional
antidepressants. Because of the potential side
effects on blood pressure due to its mechanism of
action, it should not be taken with tyramine-con-
taining foods such as cheeses, red wine, yeast, or
pickled herring. In Germany it is licensed for
depression, anxiety, and sleep disorders. It has
proven to be as effective as standard antidepres-
sants, with fewer and milder side effects, and rep-
resents fifty percent of all prescriptions for depres-
sion, totaling three million yearly.
Recent review and meta-analyses of random-
ized trials with SJW, involving 1757 outpatients
with mild to moderate depression, have been pub-
lished." Findings demonstrated that SJW was supe-
rior to placebo and as effective as amitriptyline and
imipramine. Of the twenty-three randomized con-
trol studies identified between 1983 and 1994 in
this report, none were published in English.
Recently, in the Evidence Based Medicine publica-
tion, twenty-seven studies were reported on this
compound; these included seventeen placebo-con-
trolled, and five with active comparators. 26 These
studies involved 2291 patients, who were followed
up to twelve weeks. SJW showed response in fifty-
six percent of patients versus twenty-five percent of
placebo patients. In comparator studies, fifty-one
percent of patients responded to SJW versus fifty-
two percent of patients treated with a tricyclic anti-
depressant. Inherent limitations in these studies
were the small number of patients enrolled in sin-
gle trials, low dose of comparator drugs, and
inconsistency among products tested. 27 In a drug-
monitoring study conducted on 3250 patients who
were followed by 663 different practitioners, pri-
marily internists, over a period of two to four
weeks, trials using 300 mg of SJW demonstrated
that sixty-five percent of patients were improved
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and fifteen percent were symptom free." A very
recent comparative study between SJW and fluoxe-
tine (Prozac®) in a double-blind, randomized mul-
ticenter study of 149 patients, most of whom were
women between ages sixty and eighty, with a new
diagnosis of depression, demonstrated that after a
six-week treatment period of 400 mg SJW versus
10 mg of fluoxetine, seventy-one percent of
patients responded to SJW, and seventy-two per-
cent to fluoxetine. The most common side effect of
this drug is gastrointestinal sensitivity and possibly
photosensitivity."
Insomnia
Valerian (Valeriana officinalis) is primarily used
for insomnia and anxiety. It is widely used in
Europe with more than fifty tons sold every year in
France. It enhances the activity of GABA neuro-
transmitters and can antagonize the hypnotic
effects of alcohol but not alcohol's effects on
impaired judgment and reaction time. In double-
blind studies including respectively, 128 subjects
and twenty-seven insomniacs, valerian extract
produced a significant decrease in subjectively
evaluated sleep latency scores and a significant
improvement in sleep quality in approximately
eighty-nine percent of patients. This intervention
when effective, appears to be superior to tradi-
tional hypnosedatives such as benzodiazepines,
which have the disadvantage of sedation,
decreased REM sleep and dependence, and anti-
cholinergic effects. 0
Melatonin has been promoted as a sleep aid,
antioxidant, anti-aging agent, and antidepressant.
Up to fifty percent of people over age sixty-five
complain of sleep disturbances, and forty percent
of all prescriptions for sedatives are written for
people over age sixty-five. The cause of these sleep
disturbances may be related to decreased melatonin
with normal aging, chronic disease, and drugs.
Recent studies have demonstrated the role of mela-
tonin in sleep and its use as a substitute for benzo-
diazepines to induce sleep."1 In twelve elderly
insomniacs with various illnesses, a double-blind,
placebo-controlled, crossover study of six weeks
duration with two mg melatonin demonstrated
sleep efficiency was greater with melatonin.
Melatonin has also been promoted as an anti-aging
medication. The hypothesis is that it helps reduce
the accumulation of free radicals, which may have
a damaging effect on neurons. This mechanism
may be enhanced by activity on enzymatic metabo-
lism. It appears to protect proteins and lipids in
membranes, stimulate gluthathione-peroxidase,
and to be more effective as an antioxidant than vit-
amin E or gluthathione in vitro. Extensive studies
in humans, however, have not been done. The long-
term effects of high doses of melatonin are
unknown.
Conclusions
Since there are no current regulations for nutri-
tional supplements, elderly who utilize CAM
preparations should be cautioned to use a reliable
source. The older adult must be assertive in asking
his or her doctor or pharmacist about drug interac-
tions, dosing, and the correct formulation to use.
With the increased use of herbal compounds,
healthcare professionals must be aware of potential
drug interactions. The healthcare professional has
a responsibility to guide the elderly consumer in the
interpretation of extravagant claims in light of sci-
entific evidence so that informed decisions con-
cerning CAM may be made. The elderly may not
respond to dosages tested and recommended in the
young; currently very little is known about the
response of the elderly to these products.
Consequently, older adults should not take herbal
products without first consulting a doctor or phar-
macist. Since many older adults are taking a num-
ber of prescription drugs, negative interactions are
more likely to occur. A blend of CAM with tradi-
tional medical interventions can hopefully result in
maximum patient benefit.
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